Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.43) by 95.37 percent. This is a 96.92 percent increase over losses of $(0.65) per share from the same period last year. The company reported quarterly sales of $1.024 million which beat the analyst consensus estimate of $375.750 thousand by 172.52 percent. This is a 1.71K percent increase over sales of $(63.647 thousand) the same period last year.